NATCOPHARMNatco Pharma Limited Forensic Risk Analysis

Pharmaceuticals
Risk ClassModerate Deterioration
Market Cap₹17,105 Cr
Primary DriverEarnings Quality
Flagium AI Risk Score
Moderate stress emerging. While not critical, underlying pressure is building.
49 / 100
+24 QoQ
Early Deterioration
Sentinel Insight

Some early signs of pressure are visible. Weakness is detected in profitability and earnings quality. This suggests a building risk profile. Risk is increasing at a faster pace.

100.0th %ile (Sector)Accel: +1 Qtrs
Updated2026-06-02
Market View
939.30.64%
PeriodQ4 FY26

Score Waterfall
Absolute contribution points of each forensic pillar to the final risk score. Derived from: Sector Baseline + Active Penalties - Mitigation Buffers.

Earnings Quality
+15.0 pts
Competitive Position
+15.0 pts
Growth Sustainability
+10.0 pts
Balance Sheet Stress
+8.8 pts
Final Composite Risk49 / 100

Investment Risk Thesis

Historical Trend

Current risk score has risen from 549 over 13 quarters.

Expected Direction
🚨 Escalate
Primary Deterioration Drivers
  • Margin Compression
  • Inventory Stress
  • Industrial Margin Stress
What to Watch Next Quarter
  • Operating profit margins
  • Inventory turnover
  • Debt growth

Active Risk Objects (8)

CriticalHigh
Industrial Margin Stress
📊 Earnings QualityAnnualActive for 3 Years
More Detail
Impact Weight12/15
MomentumPersistent
Last SignalQ4 FY2026
NATCOPHARM: EBITDA margin compressed by 23.1 bps YoY.

"Early signs of margin erosion. Input costs are beginning to eat into core profits."

Relative Growth Weakness
📊 Earnings QualityAnnualActive for 2 Years
More Detail
Impact Weight12/15
MomentumAccelerating
Last SignalQ4 FY2026
Revenue growth consistently lags behind sector median (13.2%).

"Early signs of earnings quality decay. Profitability is being driven by non-core items."

Margin Compression
📉 Trend DeteriorationAnnualActive for 5 Years
More Detail
Impact Weight15/15
MomentumPersistent
Last SignalQ4 FY2026
Operating margin declined by 21.7 bps YoY for two consecutive quarters.

"Early signs of margin erosion. Input costs are beginning to eat into core profits."

Inventory Stress
📊 Earnings QualityAnnualActive for 1 Years
More Detail
Impact Weight15/15
MomentumAccelerating
Last SignalQ4 FY2026
Inventory growth (18.6%) significantly outpaced revenue growth (-36.5%).

"Stock is piling up in the warehouse. Inventory turnover is slowing down dangerously."

Operating Leverage Stress
📊 Earnings QualityAnnualActive for 3 Years
More Detail
Impact Weight10/15
MomentumPersistent
Last SignalQ2 FY2026
Expenses are consistently growing faster than revenues, creating operational pressure.

"The balance sheet is heavily over-leveraged. Interest payments are consuming most of the profit."

Cash Conversion Deficit
📊 Earnings QualityAnnualActive for 3 Years
More Detail
Impact Weight6/15
MomentumPersistent
Last SignalFY2026
NATCOPHARM: OCF below Net Profit in 2/3 recent years.

"Cash conversion is dangerously low. Operational cash flow is significantly trailing reported PAT."

Working Capital Expansion
💧 Liquidity & CoverageAnnualActive for 5 Years
More Detail
Impact Weight10/15
MomentumPersistent
Last SignalQ4 FY2026
Working capital expansion detected: Receivable days increased by 11.4%.

"Early signs of working capital expansion. Receivable or inventory days are creeping up."

Revenue-Debt Divergence
🏛️ Solvency & LeverageAnnualActive for 1 Years
More Detail
Impact Weight6/15
MomentumAccelerating
Last SignalFY2026
NATCOPHARM: Revenue fell 8.5% while Debt rose 158.7% in 2026 vs 2025.

"Debt levels are creeping up. Monitor for signs of excessive borrowing for non-core activities."

Risk Trajectory
Historical 12-quarter risk trend (Q-11 to Q0) followed by a 2-quarter predictive funnel (Q+1, Q+2).
Loading Chart
Resilience Matrix
Diagnostic benchmarking comparing structural sensitivity and risk buffers against sector medians.
MetricValuevs SectorSignal
Volatility (σ)7.837.70⚠️ HIGH
Sensitivity (ε_s)11.00✅ RESILIENT
Escalation Prob.6%5%🚨 HIGH
Safety Buffer+17.0+47.0📈 CRITICAL
Forensic Benchmark Context: Pharmaceuticals (n=99 peers)

Correlation Analysis
Visualizing the relationship between stock price movement and structural risk objects.

Loading Chart
Share Price
Risk Score (0-100)
Market Performance
939.3(+0.64%)
1M Divergence-16.54%
1 Week-20.8%
1 Month-14.28%
6 Months-0.88%
1 Year+7.59%
2 Year-4.85%
3 Year+52.87%
Sector Average (1M)+2.27%
Sentinel Forensic Assessment
ALGORITHMIC RISK PROFILE • NON-ADVISORY

The risk profile is Moderate Stress and currently deteriorating. Recent structural triggers in earnings quality suggest a building pressure on the underlying framework. Material forensic traces are visible in operational margins and profitability metrics, indicating a progressive erosion of structural stability. Strategic vigilance is advised as structural decay is accelerating.

NATCOPHARM • MARKET STRUCTURE

Stage 4 — Declining

The company is in a defensive phase. Sentiment and fundamentals are deteriorating under persistent downward pressure, indicating elevated risk levels.

Stage Transition Prob.38%
Trend QualityDeteriorating
Phase Progression
Phase Progression Score35%
Readiness LabelLow (Early Base Consolidation)
Probability of Advancing38%
CoinTree Momentum
Composite Z-Score-0.7279σ
Weakening momentum trend
Universe Rank
A cross-sectional rank of this stock's composite momentum score compared to all other tracked equities in the universe. A rank of #1 of 1035 means it has the strongest overall price momentum in the market.
#2347 of 2716
Top 86.41% in momentum strength
Timeframe Sparklines
1W-20.8%
1M-14.3%
6M-0.9%
Weinstein Indicators
150 DMA950.07
200 DMA924.65
150 DMA Slope+4.6751%Rising
Relative Strength+4.61%Leading
Relative Turnover (RTR)0.7766
ParticipationWeak

PEER COMPARISON

Ranked comparison against sector peers

This company shows higher risk compared to the Sector Mean (19).

* Peer comparison is based on risk signals, not valuation or returns.

Risk Profiles

Solvency
10100th %ile
VS Sector Median (8.5)
Governance
10100th %ile
VS Sector Median (8.5)
Earnings Quality
00th %ile
VS Sector Median (8.5)
Balance Sheet Stress
5.656th %ile
VS Sector Median (8.5)
Competitive Position
00th %ile
VS Sector Median (8.5)
Growth Sustainability
00th %ile
VS Sector Median (8.5)

Deterioration Timeline

2026

Working Capital Expansion

2026

Inventory Stress

2026

Relative Growth Weakness

2026

Margin Compression

2026

Industrial Margin Stress

2026

Industrial Margin Stress

2026

Relative Growth Weakness

2026

Margin Compression

2026

Operating Leverage Stress

2026

Margin Compression

2026

Working Capital Expansion

2026

Margin Compression

2026

Industrial Margin Stress

2026

Operating Leverage Stress

2026

Revenue-Debt Divergence

2026

Cash Conversion Deficit

2025

Margin Compression

2025

Operating Leverage Stress

2025

Working Capital Expansion

2025

Cash Conversion Deficit

2024

Working Capital Expansion

2024

Working Capital Expansion

2024

Cash Conversion Deficit

Key Financials (INR Cr)

PeriodRevenueNet ProfitOCFDebt
FY20264,3761,4191,768706
FY20254,7841,8831,697273
FY20244,1271,3881,212363
FY20232,812715849165